Marco Pravetoni, PhD
The Pravetoni group focuses on development and translation of medical interventions against substance use disorders (SUD) and other chemical and biological threats. Current efforts are: 1) vaccines, monoclonal antibodies (mAb), and small molecules to treat or prevent SUD, opioid use disorders (OUD) and overdose, 2) mechanisms and biomarkers underlying or predicting efficacy of immunotherapeutics and medications in pre-clinical models of SUD and OUD patients, 3) novel strategies to enhance vaccine or medication efficacy, including immunomodulators, small molecules, adjuvants, nanoparticles, polymers and other delivery platforms, 4) Vaccines, mAb, and clinical biomarkers against infectious diseases (e.g., Pseudomonas aeruginosa and novel coronavirus SARS-CoV-2), 5) biosensors for field detection or diagnosis.
Education
PhD in Pharmacology, University of Minnesota, 2008
Department Affiliations
Scholarly Expertise
- Vaccines, monoclonal antibodies, immunology, pharmacology, chemical threats, immunoprofiling
Recent Publications
(2024 Apr 6)
Toxicol Lett 396(): 1-10
Urban K, Gkeka A, Chandra M, Greiner D, Pollich S, Ruf S, Kelemen Y, Sundermann T, Pravetoni M, Baehr C, Stebbins CE, Papavasiliou FN, Verdi JP
(2024)
Front Psychiatry 15(): 1366186
Averick SE, Kassick AJ, Song D, Zhang B, Vigliaturo J, Luengas D, Silva-Ortiz P, Pravetoni M, Raleigh MD
(2024 Feb 9)
ACS Pharmacol Transl Sci 7(2): 363-374
Song D, Crouse B, Vigliaturo J, Wu MM, Heimisdottir D, Kassick AJ, Averick SE, Raleigh MD, Pravetoni M
(2023 Oct 18)
Bioconjug Chem 34(10): 1811-1821
Powers N, Massena C, Crouse B, Smith M, Hicks L, Evans JT, Miller S, Pravetoni M, Burkhart D
(2023 Jul 24)
NPJ Vaccines 8(1): 107
Crouse B, Miller SM, Muelken P, Hicks L, Vigliaturo JR, Marker CL, Guedes AGP, Pentel PR, Evans JT, LeSage MG, Pravetoni M
Show complete publication list »
